Risk groups for success of induction and overall survival*
| Cytogenetic risk group . | Induction success . | Cumulative incidence of relapse10-151 . | Overall survival . |
|---|---|---|---|
| Favorable | t(8;21) | t(8;21) | t(8;21) |
| inv(16) or t(16;16) | inv(16) or t(16;16) | inv(16) or t(16;16) | |
| del(9q)10-152 | |||
| Intermediate | Normal karyotype | Normal karyotype | Normal karyotype |
| −Y | −Y | −Y | |
| del(5q) | t(9;11) | del(5q) | |
| t(6;9) | del(9q) | Loss of 7q | |
| t(6;11) | +8 sole | t(9;11) | |
| −7 | +8 with 1 other | +11 | |
| Loss of 7q | abnormality10-153 | del(11q) | |
| +8 sole | +11 | abn(12p) | |
| +8 with 1 other | +13 | +13 | |
| abnormality10-153 | del(20q) | ||
| del(9q) | +21 | ||
| t(9;11) | |||
| +11 | |||
| del(11q) | |||
| t(11;19)(q23;p13.1) | |||
| +13 | |||
| del(20q) | |||
| +21 | |||
| Adverse | Complex karyotype | Complex karyotype | Complex karyotype |
| (≥ 3 abnormalities) | (≥ 3 abnormalities) | (≥ 3 abnormalities) | |
| inv(3) or t(3;3) | −7 | inv(3) or t(3;3) | |
| abn(12p) | +21 | t(6;9) | |
| t(6;11) | |||
| −7 | |||
| +8 sole | |||
| +8 with 1 other | |||
| abnormality10-153 | |||
| t(11;19)(q23;p13.1) |
| Cytogenetic risk group . | Induction success . | Cumulative incidence of relapse10-151 . | Overall survival . |
|---|---|---|---|
| Favorable | t(8;21) | t(8;21) | t(8;21) |
| inv(16) or t(16;16) | inv(16) or t(16;16) | inv(16) or t(16;16) | |
| del(9q)10-152 | |||
| Intermediate | Normal karyotype | Normal karyotype | Normal karyotype |
| −Y | −Y | −Y | |
| del(5q) | t(9;11) | del(5q) | |
| t(6;9) | del(9q) | Loss of 7q | |
| t(6;11) | +8 sole | t(9;11) | |
| −7 | +8 with 1 other | +11 | |
| Loss of 7q | abnormality10-153 | del(11q) | |
| +8 sole | +11 | abn(12p) | |
| +8 with 1 other | +13 | +13 | |
| abnormality10-153 | del(20q) | ||
| del(9q) | +21 | ||
| t(9;11) | |||
| +11 | |||
| del(11q) | |||
| t(11;19)(q23;p13.1) | |||
| +13 | |||
| del(20q) | |||
| +21 | |||
| Adverse | Complex karyotype | Complex karyotype | Complex karyotype |
| (≥ 3 abnormalities) | (≥ 3 abnormalities) | (≥ 3 abnormalities) | |
| inv(3) or t(3;3) | −7 | inv(3) or t(3;3) | |
| abn(12p) | +21 | t(6;9) | |
| t(6;11) | |||
| −7 | |||
| +8 sole | |||
| +8 with 1 other | |||
| abnormality10-153 | |||
| t(11;19)(q23;p13.1) |
Patients are assigned to risk group according to probability of attaining a CR. Patients were assigned in the following order: normal karyotype→t(8;21), inv(16)/t(16;16), and t(9;11)→complex karyotype with at least 3 abnormalities→other groups as outlined in the text. Abnormalities not specified are not included in the risk assessment model.
Too few patients with inv(3) or t(3;3), del(5q), t(6;9), t(6;11), loss of 7q, del(11q), t(11;19)(q23;p13.1), abn(12p), and del(20q) achieved a CR to be classified according to their cumulative incidence of relapse.
del(9q) would be assigned to the intermediate-risk group if only patients not undergoing transplantation were analyzed (see footnote designated by “†” in Table 9).
An abnormality accompanying +8 is other than t(8;21), t(9;11), and inv(16) or t(16;16).